Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151112 | 0.86 | KMT2A (0.56) | KMT2ATACR1LMNANPC1HTT | |
| SCHEMBL21150772 | 0.84 | ITGB3 (0.38) | TACR1LMNANPC1RAB9A | |
| SCHEMBL24974777 | 0.80 | KMT2A (0.47) | KMT2ATACR1LMNANPC1HTT | |
| SCHEMBL3245801 | 0.79 | KMT2A (0.56) | KMT2ATACR1LMNANPC1HTT | |
| SCHEMBL9965983 | 0.71 | KMT2A (0.71) | KMT2ALMNANPC1HTTRAB9A | |
| SCHEMBL21764913 | 0.71 | GPR119 (0.52) | LMNANPC1HTTRAB9A | |
| SCHEMBL4834401 | 0.69 | LMNA (0.48) | KMT2ATACR1LMNANPC1HTT | |
| SCHEMBL21150801 | 0.69 | L3MBTL1 (0.54) | KMT2ALMNANPC1HTTRAB9A | |
| SCHEMBL23288913 | 0.69 | OPRD1 (0.46) | KMT2ATACR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3392659 | 0.69 | LMNA (0.50) | KMT2ALMNANPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KMT2A 499/4885TACR1 76/4885LMNA 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.